- Services Overview
- Analytes Details
- FAQ
Neurodegenerative Disease in Mouse
Since the genetic and physiological similarities between mice and humans are strong, neurodegenerative diseases in mice are often studied to understand similar conditions in humans. These diseases include a variety of disorders in which there is a progressive deterioration in the structure and function of the nervous system. Common neurodegenerative diseases modeled in mice include Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). Mouse models are utilized because they allow for the manipulation of specific genes and observation of the resulting effects on the nervous system. This helps to deepen the understanding of the pathological processes involved and to identify potential therapeutic targets. The use of mice in neurodegenerative disease research is critical not only for understanding disease mechanisms, but also for evaluating the efficacy and safety of new therapies prior to human trials. This research has the potential to significantly contribute to the development of interventions that can prevent, slow or reverse the progression of these debilitating diseases.
Mouse Neurodegenerative Disease Panel at Creative Proteomics
Creative Proteomics uses Luminex xMAP Technology to provide comprehensive and reliable Mouse Neurodegenerative Disease Panel analysis. This platform enables the simultaneous detection and quantification of multiple biomarkers with high sensitivity and specificity, tailored to the unique needs of neurodegenerative disease research. By offering a precise and efficient solution, we support researchers in uncovering critical insights into disease mechanisms and advancing therapeutic development.
Detection Method
Magnetic bead-based Luminex multiplex assay
Species
Mouse
Analytes Detected
| Species | Specification | Protein Targets | Applications | Price |
|---|---|---|---|---|
| Mouse | Mouse Neurodegenerative Disease 7-plex Panel | C-Reactive Protein/CRP, CCL5/RANTES, PDGF-AA, PDGF-BB, RAGE/AGER, Serpin E1/PAI-1, ICAM-1/CD54 | Suitable for studying biomarkers related to neuroinflammation, neuronal repair, oxidative stress, and disease pathways. | +Inquiry |
Sensitivity (Detection Limits)
- C-Reactive Protein (CRP): 8–12 pg/mL
- CCL5 (RANTES): 3–7 pg/mL
- PDGF-AA: 12–18 pg/mL
- PDGF-BB: 15–25 pg/mL
- RAGE (AGER): 20–30 pg/mL
- Serpin E1 (PAI-1): 6–10 pg/mL
- ICAM-1 (CD54): 10–15 pg/mL
Advantages of Mouse Neurodegenerative Disease Luminex Assay
High Sensitivity and Precision
- Capable of detecting biomarkers at low picogram levels, ensuring accurate quantification of even scarce proteins.
- Minimizes variability with precise multiplexing, delivering consistent and reproducible results.
Multiplexing Efficiency
- Simultaneously analyzes 7 key neurodegenerative biomarkers in a single reaction, reducing time and sample requirements.
- Optimized for small-volume samples, such as serum, plasma, or cerebrospinal fluid from mouse models.
Wide Dynamic Range
- Accurately quantifies biomarkers over a broad concentration range, accommodating diverse research needs.
Cost and Time Efficiency
- Combines the benefits of high-throughput analysis with reduced reagent and labor costs compared to single-target assays.
- Accelerates the research timeline by consolidating multiple assays into one.
Comprehensive Panel Design
- Includes biomarkers relevant to neuroinflammation, neuronal repair, oxidative stress, and vascular integrity, providing a holistic view of disease mechanisms.
Customizable and Flexible
- Compatible with various sample types, including tissue lysates and conditioned media, enabling diverse experimental setups.
- Offers the option for tailored assay panels to meet specific research goals.
Validated and Reliable Technology
- Powered by Luminex xMAP Technology, a proven platform for multiplex biomarker analysis with high reproducibility and minimal cross-reactivity.
Sample Requirements for Mouse Neurodegenerative Disease Luminex Panel
| Sample Type | Minimum Volume Required | Optimal Storage Conditions | Remarks |
|---|---|---|---|
| Serum | ≥ 50 µL | Store at -80°C | Collect using a clot activator, centrifuge to separate serum, and avoid repeated freeze-thaw cycles. |
| Plasma | ≥ 50 µL | Store at -80°C | Use EDTA or heparin as anticoagulants; centrifuge to separate plasma and avoid hemolysis. |
| Cerebrospinal Fluid | ≥ 50 µL | Store at -80°C | Collect under sterile conditions and ensure no contamination with blood. |
| Tissue Lysates | ≥ 100 µg of protein | Store at -80°C | Prepare lysates using appropriate lysis buffer and ensure removal of debris by centrifugation. |
| Conditioned Media | ≥ 500 µL | Store at -80°C | Collect cell culture supernatant, centrifuge to remove cells, and filter if necessary. |
Application of Mouse Neurodegenerative Disease Panel
- Biomarker Discovery and Validation: Enables the identification and confirmation of critical biomarkers associated with neurodegenerative diseases, providing a foundation for therapeutic target development.
- Mechanistic Studies: Facilitates the investigation of biological pathways involved in inflammation, oxidative stress, and neuronal repair, offering insights into disease mechanisms.
- Preclinical Drug Development: Supports the evaluation of drug candidates by monitoring biomarker changes in response to therapeutic interventions, ensuring data-driven decision-making in preclinical studies.
- Model Validation: Helps characterize and validate mouse models of neurodegenerative diseases to ensure their relevance and alignment with human disease conditions.
- Treatment Assessment: Assists in monitoring the impact of treatments, including efficacy and potential off-target effects, through reliable biomarker profiling.
In addition to preconfigured panels, we also offer customized analysis services. You can customize your own panel through our customization tool, or directly email us the targets you are interested in. A professional will contact you to discuss the feasibility of customization. We look forward to working with you!
| Protein Target | Description |
|---|---|
| C-Reactive Protein (CRP) | An acute-phase protein produced in response to inflammation; a biomarker for systemic inflammation and linked to neurodegenerative diseases like Alzheimer's and Parkinson's. |
| CCL5 (RANTES) | A chemokine involved in immune cell recruitment and inflammation; plays a significant role in neuroinflammatory responses and neurodegenerative conditions. |
| PDGF-AA | A growth factor critical for cell proliferation, neuroprotection, and tissue repair; regulates neurogenesis and glial cell activation in neurodegenerative diseases. |
| PDGF-BB | Promotes neuroprotection and cellular repair; associated with neuroinflammation and tissue remodeling in neurodegenerative disease models. |
| RAGE (AGER) | A receptor involved in inflammatory processes, oxidative stress, and neurodegeneration; key in Alzheimer's and other neurodegenerative disorders. |
| Serpin E1 (PAI-1) | Regulates fibrinolysis and extracellular matrix remodeling; implicated in neuroinflammatory processes and neuronal damage in neurodegenerative diseases. |
| ICAM-1 (CD54) | A cell adhesion molecule critical for leukocyte migration and blood-brain barrier integrity; elevated in neuroinflammatory conditions contributing to neurodegeneration. |
How does the Luminex xMAP Technology ensure minimal cross-reactivity in the multiplex assay?
The Luminex xMAP Technology employs precisely designed magnetic beads coated with highly specific capture antibodies for each analyte. The technology minimizes cross-reactivity through:
- Unique bead encoding: Each analyte is associated with a uniquely fluorescent bead, reducing interference between targets.
- Optimized assay protocols: Stringent washing steps and optimized buffer formulations prevent non-specific binding.
- Quality control: Each batch of beads and antibodies is validated for minimal cross-reactivity, ensuring assay reliability.
How is data from the assay delivered, and what information is included?
Results are delivered in a comprehensive report that includes:
- Raw Data: Mean fluorescence intensity (MFI) for each analyte in all samples.
- Processed Results: Concentrations calculated based on standard curves with appropriate dilutions accounted for.
- Quality Control Metrics: Details of assay performance, including standard curve fitting, sensitivity, and intra-/inter-assay variability.
- Optional Analysis: Statistical comparisons, heatmaps, or pathway analyses, if requested.
What quality control measures are implemented during the assay?
Creative Proteomics employs rigorous quality control protocols, including:
- Standard Curves: Each assay includes high-quality standards for accurate quantification.
- Replicate Testing: Samples and standards are run in duplicates or triplicates to ensure consistency.
- Controls: Internal and external controls verify assay sensitivity and specificity.
- Validation: Each assay is pre-validated for inter- and intra-assay variability.
